Objective: Patent ductus arteriosus (PDA) is a common condition among preterm infants. Controversy exists regarding the risk-benefit ratio of early closure of PDAs by either medical or surgical treatments. On the other hand, potential morbidities associated with no or delayed closure has not been well studied. The objective of the study was to determine if there is an association of prolonged persistent PDA (PP-PDA) with various morbidities in infants p28 weeks or 1250 g.
Introduction
Patent ductus arteriosus (PDA) is a common problem among preterm babies. The frequency that a preterm baby develops a left to right shunt that is hemodynamically significant is inversely proportional to gestational age and birth weight, reaching an incidence between 65 and 80% in neonates born at <26 weeks and 1000 g. [1] [2] [3] [4] [5] Ductal closure depends on many factors including muscular constriction and anatomical remodeling and is directly related to its structural maturity correlating with gestational age. 1 Its persistence after birth does not only have well known physiological effects, but also has been associated with negative effects and complications in many organs, including left ventricular insufficiency, pulmonary edema and hemorrhage, bronchopulmonary dysplasia (BPD), [6] [7] [8] [9] [10] oliguria, renal failure, necrotizing enterocolitis (NEC), 11, 12 periventricular leukomalacia and intracranial bleeding. 13, 14 Despite this information, in the past several years there has been controversy about whether or not to treat the ductus early, or at all, in preterm babies, 15, 16 with concern about the potential risks of doing so.
The incidence of PDA and its closure are impacted to a larger or lesser extent by clinical decisions made at the bedside, which may be associated with a prolonged persistence of a ductus that is hemodynamically significant. Clinical decisions that have an impact on PDA include, among others: negative water intake with adequate weight loss during the first days of life (correlated with less ductus incidence), [17] [18] [19] use of furosemide (more PDA and lower closure rate) [20] [21] [22] [23] and excessive volume expansions such as the administration of saline bolus solutions. Furthermore, when a hemodynamically significant PDA is diagnosed in a preterm baby, clinical decisions about medical and/or surgical treatment will of course have an influence on the ultimate outcome of the PDA.
The doubts and controversies regarding the clinical significance and treatment of the ductus in preterm babies are likely because of three reasons. First is that all the alternatives to close the PDA have negative effects. [24] [25] [26] [27] [28] A second one is that, with time, an important number of PDA's close spontaneously. [29] [30] [31] The third one is that this clinical condition has a wide range of severity. There are many infants in whom PDA's have no clinical significance, whereas others may have severe ventricular insufficiency and pulmonary edema. Nowadays, there are several approaches to PDA in the NICU and the clinical practices include prophylactic use of non-steroidal anti-inflammatory drugs (NSAID), medical early or late treatment with one, two or even three courses of NSAIDs, surgical closure, and observation and even no treatment at all. [32] [33] [34] [35] [36] [37] As amidst many clinical studies there is not much studied about infants who have PDAs which last for more than three weeks, we designed this study with the aim to determine if the prolonged persistence of the PDA (PP-PDA) for >3 weeks is associated with greater morbidity in preterm infants <1250 g.
Methods
This is a matched case-control study performed in inborn preterm infants in a level III NICU in USA. During a period of 28 consecutive months we prospectively enrolled infants that were p28 weeks gestation and <1250 g who had a PDA, excluding infants that had been treated with prophylactic indomethacin.
Clinical management and therapeutic approaches, including timing of echocardiogram, were done at the discretion of the attending neonatologist. The standard protocol for PDA medical treatment included three doses of indomethacin at 0.2, 0.1 and 0.1 mg kg À1 if the newborn was <48 h old and 0.2, 0.2 and 0.2 mg kg À1 if >48 h. An investigator blinded to the study collected data into a database using electronic medical records.
PDA was defined as a ductus >1.5 mm of diameter by echocardiogram and at least two clinical signs associated with the presence of a left to right shunt, such as hyper dynamic precordium, full or bounding peripheral pulses, a pulse pressure >25 mm Hg, low diastolic pressure for age, continuous or systolic murmur, cardiomegaly and pulmonary edema.
As routinely evaluated by pediatric cardiologists, an echocardiogram was repeated in all infants in whom PDA was diagnosed, after treatment with indomethacin or after 3 to 10 days when no NSAID was used. In those echocardiogram, PDA was defined as 'closed' if no flow was seen through the ductus. A PP-PDA was defined if the PDA was still opened with flow trough the ductus and clinical signs as above at 21 days of postnatal age or later.
For this case-control study the newborns with PP-PDA were the cases. The matched controls were babies who had a PDA that had closed before 21 days of life, either spontaneously or with medical or surgical intervention. Per unit protocol, surgical ligation was never used as a first line of treatment, except if there were clear contraindications for use of indomethacin. After at least one full course of indomethacin, ligation was decided in each case at the discretion of the attending neonatologist and cardiologist.
We included two controls for each case and they were matched according to the following criteria: prenatal use of steroids, birth weight, gestational age, Apgar score and severity of illness by Score of Neonatal Acute Physiology with Perinatal Extension.
The predictive variable was the presence of a PP-PDA, either because no medical or surgical treatment was used by medical decision (not because of contraindication of treatment) or because partial or complete medical treatment was administered but it was not effective. Primary outcome variables included number of days on mechanical ventilation, number of days on oxygen, total number of hospital days, the development of severe BPD defined as requirement of respiratory support and/or need for oxygen at 36 weeks post gestational age corrected and need for oxygen at the time of discharge to home.
As secondary outcome variables we evaluated the rate of several morbidities. Among them were NEC (Bell's Stage II or above), retinopathy of prematurity (ROP) stage III or greater, presence of serum direct hyperbilirubinemia (conjugated bilirubin) >4 mg dl À1 , osteopenia of prematurity (presence of alkaline phosphatase level >750 mg dl À1 or fractures on long bone x-rays), parenteral nutrition for >40 days, tracheostomy during the hospitalization and poor nutritional state at discharge (postnatal growth <20 percentile).
Based on clinical protocols, all infants in this birth weight category have a head ultrasound performed within 3 days after birth, which is repeated weekly as needed, and also close to time of discharge. Radiologists, unaware of group assignment, diagnosed and classified severity of intraventricular hemorrhage (IVH) as routinely performed.
As part of this study we also assessed potential associations between PP-PDA with some practices early in postnatal life. Among them we evaluated the use of at least two doses of 10 ml kg À1 of intravenous saline boluses in the first 72 h of life, and weight change in the first week of life as a surrogate of water balance. We defined adequate negative water balance a weight loss of 8 to 15% in the first 7 days of life. Finally, we also evaluated furosemide use, defined as at least two doses of 1 mg kg À1 per dose in the following circumstances: (a) together with NSAID treatment for PDA, (b) for oliguria as considered per attending MD and (c) for PDA management without NSAID.
Data was handled confidentially and without patient identification. Comparison of cases and controls was performed using w 2 to compare groups and the independent t-test and ANOVA for comparison of continuous variables between groups. Significance was set at P<0.05.
For this matched case control study there were no interventions other the ones routinely used by attending neonatologists. The Internal Review Boards and Ethics boards approved the study. Informed consent was not required.
Results
There were a total of 84 infants in the study; 28 infants had PP-PDA and 56 infants had a PDA that closed in <21 days. Mean duration of PP-PDA was 49 days, with a range between 35 and 86 days. By design, the Apgar score, prenatal use of steroids, birth weight, gestational age and Score of Neonatal Acute Physiology with Perinatal Extension were similar, as shown in Table 1 .
Of the 28 babies with PP-PDA, 10 did not receive indocin treatment at time when PDA was first diagnosed. They were all surgically ligated after 5 weeks of age. The other 18 infants failed to close the PDA after receiving one to three courses of indomethacin. In 14 of them PDA closed after 40 days, either surgically (n ¼ 12) or spontaneously. Four infants were discharged home without documentation of ductal closure.
In the matched control group all infants received indomethacin. Failure rate was 11% and these infants were all ligated before 3 weeks of age. Table 2 shows that infants with PP-PDA had a significantly greater risk for the primary outcomes studied. The total number of days on mechanical ventilation, number of days on oxygen, length of hospital stay and rates of BPD and use of oxygen at the time of discharge were all significantly worse in cases compared with controls. In Table 3 comparisons of secondary outcomes are shown. Babies with PP-PDA presented statistically worse rates of NEC, ROP, direct hyperbilirubinemia, osteopenia of prematurity, parenteral nutrition for >40 days, tracheostomy during the hospitalization and poor nutritional state at discharge.
As expected, the incidence of IVH grades III-IV was almost identical in both groups (4%). In all infants IVH occurred before 96 h of age.
Finally, newborns with PP-PDA received saline boluses more frequently compared with the matched controls (60% vs 8%, respectively). Additionally, 72% of infants with PP-PDA vs 20% with no PP-PDA did not have negative water balance (i.e., no adequate weight loss) in the first 7 days of life. Moreover, 50% of the infants with PP-PDA and inadequate weight loss did not lose any weight or actually gained weight. Lastly, 62% of infants with PP-PDA had received furosemide vs 12% of those who had PDA but did not develop PP-PDA. All these differences were statistically significant (P<0.05).
Discussion
The findings of this study show that a persistently prolonged PDA due to failure of medical therapy or to a clinical decision of no treatment is not inconsequential and may be associated with serious morbidities.
Prior studies have reported that preterm babies with persistent ductus have increased morbidity and also mortality. [39] [40] [41] [42] [43] For example, three publications [39] [40] [41] reported that infants with a PDA for >2 weeks gained less weight postnatally, needed more days to reach full feeds, required more days of mechanical ventilation and required oxygen at discharge more frequently. In our study, if a hemodynamically significant PDA persisted for >3 weeks, the risk of important morbidity like severe BPD, ROP, NEC, direct hyperbilirubinemia, osteopenia and delayed growth increased. Furthermore, in our study infants with PP-PDA had a more prolonged hospital stay and required more days of ventilation and Prolonged persistent PDA YP Saldeñ o et al oxygen therapy, which can be related to the physiology of the hemodynamically significant PDA with a left to right shunt affecting pulmonary and systemic circulation, generating low systemic circulation and pulmonary overload. 38 The compromised systemic blood flow may affect oxygen delivery to tissues and can result in multisystem failure. Excessive pulmonary blood flow for a long time may lead to pulmonary edema, alterations in alveolar and vascular structure development and vascular lung disease. These situations may lead to respiratory failure, unsuccessful attempts to extubation and/or BPD. These hemodynamic repercussions may be more important in sicker preterm babies. 39, 40 In our study the rates of BPD were significantly higher in newborns with PP-PDA. Strikingly, 7 of the 28 infants developed BPD with pulmonary hypertension of such severity that required treatment with pulmonary vasodilators and vasoactive drugs. 44 Even though the numbers are not sufficient to evaluate them adequately through statistical analysis, the finding lends some further support to the consideration that there are some babies that do not tolerate the persistence of an important PDA. We speculate that for such babies earlier closure of a hemodynamically significant PDA may improve their clinical course and outcome.
The incidence of IVH was very similar between the two groups. This is not surprising as all hemorrhages occurred early, all infants had PDA and PP-PDA would not be expected to cause IVH this late in postnatal life.
During the first days of life, preterm infants often need an individualized and strict control of water intake to promote negative water balance and adequate weight loss without dehydration. This practice has been associated with less risk of PDA, NEC, BPD and death. 17, 45 In the current study we found that a high percentage of newborns with PP-PDA did not have adequate weight loss, gained weight or received saline boluses in the first days of life when compared with the matched controls.
Controlled studies had previously shown a higher prevalence of PDA in newborn infants treated with furosemide, [21] [22] [23] possibly because of furosemide's inhibition of a prostaglandin inhibitor, which could potentially decrease or minimize ductal response to NSAID treatment. Additionally, there is current lack of evidence to support the administration of furosemide to premature infants treated with indomethacin for symptomatic PDA. 46 Despite this, in this study about two thirds of the infants with PP-PDA had received furosemide. Whether improving practices for more adequate water balance and decreasing or eliminating furosemide use during the first week in high risk infants will have a preventive effect on the persistence of PDA cannot be proven by this study and remains to be well studied.
More than three decades after the first reports of medical treatment of the PDA, 47, 48 management remains heterogeneous and controversial and ideal timing and criteria for various treatments remain still to be established. [49] [50] [51] [52] Some authors have concluded that there is a need for new controlled, randomized trials to reexamine the benefits and risks of different approaches to PDA treatment 35, 37 and others considered that clinical trials are needed to determine whether any interventions intended to close the PDA reduce mortality and morbidity rates. 53 We would add that there is also a need to identify the subset of infants who are at high risk for developing a PP-PDA and to ascertain the best preventive and/or therapeutic approach for those infants. The findings in this study suggest that selective treatment can be of value in some infants and that, whatever the involved factors and causes may be, it seems prudent to aim to individualize infants in whom avoiding a prolonged and persistent hemodynamically significant PDA may improve outcome. Making efforts to implement some practices and eradicate others to diminish the risks of serious neonatal morbidities may have an impact in decreasing adult diseases of neonatal origin. As the late Bill Silverman said: 54 'we cannot always make our patients better, but we can always make them worse. ' There are of course limitations to the current study. First, this is not a multicenter prospective controlled study, which would provide the best level of evidence. However, in this masked case-control design we matched cases and controls by several strict criteria, including disease severity evaluated by Score of Neonatal Acute Physiology with Perinatal Extension. [55] [56] Finally, by design this study does not provide information about what to do regarding prophylaxis of PDA or for PDA's of small size without any hemodynamic significance.
Conclusion
A prolonged exposure to PDA does not seem to be inconsequential and is associated with an increase prevalence of severe morbidities with potential for long lasting effects. The natural evolution of a hemodynamically significant PDA persisting for >3 weeks may be highly detrimental for some infants.
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